Login to Your Account

Dong-A expands global footprint with Tobira in cross-licensing deal

By Haky Moon
Staff Writer

Friday, April 22, 2016

HONG KONG – Dong-A ST. Co. Ltd., an 84-year-old South Korean pharmaceutical company, recently inked two separate licensing agreements with Nasdaq-listed Tobira Therapeutics Inc., as a further sign that Korean firms are reaching deeper into the global biopharma scene through licensing agreements with multinationals.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription